Latuda (Lurasidone)

Lurasidone blocks dopamine D2 and serotonin 5‑HT2A receptors while partially stimulating 5‑HT1A receptors and blocking 5‑HT7 receptors. This mixed activity balances dopaminergic and serotonergic pathways, which underlies its antipsychotic and mood‑stabilising properties.

The appropriate dose of Latuda is individualized by the prescribing clinician based on the patient’s diagnosis, response, and tolerability. Starting doses, titration steps and maximum limits are defined in the product label, and the prescriber determines the exact regimen for each patient.

Safety data for lurasidone in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives and risks with their healthcare provider.

To request Latuda, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with many atypical antipsychotics, lurasidone has a relatively low risk of metabolic side effects such as weight gain and dyslipidaemia, while still providing robust efficacy for schizophrenia and bipolar depression. Its receptor profile also offers a modest antidepressant effect, distinguishing it from agents that focus primarily on psychosis.

Latuda tablets should be stored at room temperature, below 25 °C (77 °F). Keep them in the original blister pack, protect from moisture and direct sunlight, and store out of reach of children.

Latuda is taken orally as a whole tablet, usually once daily with food to enhance absorption. Patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their clinician, without crushing or chewing the tablet.

Serious risks include the potential for tardive dyskinesia, neuroleptic malignant syndrome, severe neutropenia or agranulocytosis, seizures, and emergent suicidal thoughts or behaviours, particularly early in treatment. Prompt medical attention is required if any of these events occur.

Latuda is contraindicated in patients with known hypersensitivity to lurasidone or any of its excipients. Caution is advised for individuals with severe hepatic impairment, a history of prolonged QT interval, or those currently taking strong CYP3A4 inhibitors or inducers without appropriate dose adjustments.